Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review Yavropoulou MP; Kotsa K; Gotzamani Psarrakou A; Papazisi A; Tranga T; Ventis S; Yovos JGHormones (Athens) 2010[Jul]; 9 (3): 274-8X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form of hypophosphatemic rickets. Standard treatment of XLH patients includes long-term administration of phosphate and calcitriol. Treated patients usually respond well to the conventional therapy and demonstrate amelioration of rachitic symptoms and improved growth. However, long-term administration of phosphate and vitamin D preparations is sometimes complicated with nephrocalcinosis, secondary or tertiary hyperparathyroidism and arterial hypertension. We describe a patient with XLH, caused by a rare missense mutation of the PHEX gene. The patient, while under treatment with alphacalcidol and oral phosphate, developed hypercalciuria, nephrocalcinosis, secondary hyperparathyroidism and arterial hypertension. Cinacalcet was added to the therapeutic regimen and the long-term effects on calciotropic parameters and FGF23 levels are herein reported.|*Genetic Diseases, X-Linked[MESH]|Adult[MESH]|Biomarkers/blood[MESH]|Bone Density Conservation Agents/*adverse effects[MESH]|Calcifediol/blood[MESH]|Calcium/blood[MESH]|Cinacalcet[MESH]|Familial Hypophosphatemic Rickets/complications/*drug therapy[MESH]|Female[MESH]|Fibroblast Growth Factor-23[MESH]|Fibroblast Growth Factors/blood[MESH]|Humans[MESH]|Hydroxycholecalciferols/*adverse effects[MESH]|Hyperparathyroidism, Secondary/blood/chemically induced/*drug therapy[MESH]|Hypertension/chemically induced/drug therapy[MESH]|Mutation, Missense[MESH]|Naphthalenes/*therapeutic use[MESH]|PHEX Phosphate Regulating Neutral Endopeptidase/genetics[MESH]|Parathyroid Hormone/blood[MESH]|Phosphates/*adverse effects[MESH]|Treatment Outcome[MESH] |